ZBTB7A is a pleiotropic transcriptional repressor that regulates diverse cellular processes through chr19 modification and direct DNA binding. The protein functions as a key regulator of cell proliferation, differentiation, and apoptosis by binding to specific DNA consensus sequences and recruiting corepressor complexes 1. In erythroid development, ZBTB7A acts as a direct fetal γ-globin transcriptional repressor, with hydroxyurea treatment reducing its protein levels to induce fetal hemoglobin expression 2. The transcription factor plays crucial roles in hematopoietic malignancies, where mutations in ZBTB7A are associated with poor prognosis in myeloid leukemias 34. In acute myeloid leukemia, ZBTB7A inactivation contributes to MYC pathway upregulation, suggesting potential therapeutic targeting with bromodomain inhibitors 4. ZBTB7A also functions in solid tumors, where it modulates KDM5-driven transcriptional networks in breast cancer and affects treatment response 5. Beyond cancer, ZBTB7A dysregulation in brain astrocytes contributes to major depressive disorder pathophysiology by promoting stress susceptibility through altered astrocyte-neuronal communication 6. The protein's diverse functions across multiple tissue types and disease contexts make it an attractive therapeutic target for various conditions.